What changed › 2026-09-02
Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes
Detected 2026-09-02 in the trials record for semaglutide, by comparing that day’s fetch against the previous one.
A completion date is the sponsor's estimate of when the main result will be in hand. ClinicalTrials.gov overwrites the old date when it moves, keeping no public history, so the previous value below exists nowhere else.
What changed
| Change | Field | Value |
|---|---|---|
| results date moved | primary_completion_date | 2027-09-20 → 2026-01-20 |
What the record says now
- Status
- Completed
- Phase
- P2
- Participants
- 114
- Primary completion
- 2026-01-20
- Sponsor
- Mostafa Bahaa
See semaglutide · NCT06762314 · the source record.
The previous value above is not recoverable from the source. Both ClinicalTrials.gov and the FDA revise records in place, keeping no public history, which is why this site keeps its own.